Tongrentang (03613) announced its annual performance, with a net profit attributable to shareholders of HK$397 million, a decrease of 20.6% year-on-year.

TONGRENTANGCM (03613) announces its annual results for the year ending December 31, 2025. The group achieved a revenue of HK$1.513 billion, a decrease of 6.1% year-on-year. The company's attributable profit was HK$397 million, a decrease of 20.6% year-on-year. Earnings per share were HK$0.47, and a final dividend of HK$0.37 per share is proposed. The announcement stated that revenue in the Hong Kong market decreased by 11.9% year-on-year, mainly due to the group's strengthening and optimizing of sales channels in the Hong Kong market in the second half of the year, consolidating the main product market base, and reducing wholesale of main products, while retail revenue remained stable year-on-year. Revenue in the China mainland market increased by 18.3% year-on-year, mainly due to increased sales of cracked spore powder capsules of lingzhi and traditional Chinese medicine products. Revenue in overseas markets remained stable, with a slight increase of 0.9% year-on-year.